Summary prepared by Rowan Zyada Nephrologist, Kidney and urology center, Alexandria, Egypt Kidney and urology center, Alexandria, Egypt Sejal Lakhani Internal Medicine Resident, Lehigh Valley Health Network, Allentown, PA Lehigh Valley Health Network, Allentown, PA NSMC interns Class of 2024 Reviewed by Swapnil Hiremath , Jade Teakell , Pallavi Prasad , Brian Rifkin , Cristina Popa , Sayali Thakare Header Image created by AI, based on prompts by Evan Zeitler Header Image created by AI, based on prompts by Evan Zeitler
View Article European Journal of Pharmacology (1999) "Pharmacological characterisation of Ipamorelin, a new growth hormone secretagogue." View Article Growth Hormone & IGF Research (1999) "Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats." View Article
LIR was also shown to cross the BBB following intraperitoneal administration at 25 and 250 nmol/kg, while no measurable increase in brain levels was detectable at the lowest tested dose, 30 min post-injection, nor at a later time point (3 h), even with the highest dose suggesting that LIRs brain penetration is both dose- and time-dependent (Hunter and Hlscher, 2012)
Obesity disproportionately impacts individuals with the fewest financial resources. Novo Nordisk also offers these medications directly from its manufacturers pharmacy at the same price